Reading the Mounjaro SmPC: what the prescribing document actually says

What the SmPC is, and why it matters to you as a patient

Most people come across the Mounjaro SmPC because they want certainty about something: a specific contraindication, an interaction with another medicine, or exactly what the licensed dose schedule looks like. That instinct is a good one. The SmPC is the document the MHRA evaluated when it granted marketing authorisation for tirzepatide, and every prescriber in the UK is expected to know its contents.

Structurally, the document is divided into numbered sections. Section 4 is where the clinical substance lives: 4.1 covers the licensed indication, 4.2 gives dosing, 4.3 lists absolute contraindications, 4.4 carries special warnings and precautions, 4.5 discusses interactions, and 4.8 details side effects. Section 5 covers pharmacology (the dual GIP and GLP-1 receptor mechanism) and Section 6 covers storage. You can read the Mounjaro SmPC on the Electronic Medicines Compendium, which is kept updated after any post-authorisation changes.

One thing worth knowing: the SmPC is written for healthcare professionals, not patients. The language can be dense, and dose-adjustment guidance is deliberately framed for prescribers rather than for self-management. If a section leaves you uncertain, that uncertainty is exactly what a prescriber is there to resolve.

What the SmPC says about licensed use and who qualifies

Section 4.1 of the Mounjaro SmPC UK version confirms two licensed indications: weight management in adults (alongside a reduced-calorie diet and increased physical activity) and type 2 diabetes. For weight management, the threshold is a BMI of 30 or above, or a BMI of 27 to 29.9 alongside at least one weight-related comorbidity, high blood pressure, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease or type 2 diabetes are the conditions referenced in clinical practice.

The document also carries a Black Triangle (▼) designation, meaning the MHRA requires additional monitoring of tirzepatide while longer-term data accumulates. That status does not imply the medicine is unsafe; all new medicines in the UK carry it initially. You can read the NHS tirzepatide page for a patient-level summary of the same licensed information.

The SmPC does not prescribe for individuals. It describes the population studied and the conditions under which tirzepatide showed a favourable risk-benefit balance. Whether you fall inside that population (and at which dose) is what a prescriber determines by reviewing your full medical picture. If you are thinking about what treatment might look like for you, our free consultation is the appropriate starting point.

The dosing schedule in the SmPC, and what it does and does not tell you

Section 4.2 sets out the dose escalation schedule: tirzepatide begins at 2.5 mg once weekly. The 2.5 mg dose is there to let your system adjust, the SmPC is explicit that it is a starting dose for tolerability, not the maintenance dose. Titration then proceeds through 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg, typically in four-week steps, with the prescriber selecting the appropriate maintenance dose for each patient.

The SmPC also covers what to do if a dose is missed, injection sites (abdomen, thigh and upper arm, rotated), and storage conditions. On storage, the document gives a specific room-temperature window, the number of days the pen may be kept outside the fridge. We do not repeat that figure here because it is a detail that must be read directly from the current SmPC or the PIL inside the box; those sources are authoritative and updated, whereas secondary sources can lag. For dose-specific questions about the 2.5 mg starting pen or moving to the 5 mg dose, the underlying SmPC section 4.2 applies equally.

Critically, the SmPC does not tell you what dose you should be on. It describes the permitted schedule. Decisions about when to increase, hold or reduce are clinical judgements made by your prescriber based on your response and tolerability, never based on reading section 4.2 in isolation. If you feel the current dose is not right for any reason, the right move is a conversation with your prescriber rather than self-adjusting.

Contraindications, warnings and interactions in sections 4.3–4.5

Section 4.3 lists absolute contraindications, situations where tirzepatide must not be used. These include hypersensitivity to tirzepatide or any excipient, and a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. The SmPC is unambiguous on these points, and a thorough prescriber reviews them before every new prescription.

Section 4.4 carries the special warnings. Pancreatitis appears here as a risk requiring patient awareness, the MHRA reinforced this point in a January 2026 Drug Safety Update, and the SmPC asks prescribers to counsel patients to seek urgent help for severe, persistent abdominal pain, especially if it radiates to the back. Gallbladder disease, dehydration from gastrointestinal side effects, and the effect on oral contraceptive absorption are also covered in this section. For tirzepatide specifically, women using the pill are advised to add a barrier method for the first four weeks of treatment and for four weeks after each dose increase.

Section 4.5 addresses interactions. Slowed gastric emptying affects how quickly other oral medicines are absorbed, section 4.5 discusses this in detail, including relevance to oral contraceptives. The interaction question comes up often enough that our prescribers field it regularly. For broader context on what tirzepatide interactions look like in practice, or to learn more about how Mounjaro works as a treatment, those pages build on the SmPC's clinical framework in plain language, and patients who are also exploring e Mounjaro as part of their options will find that the same SmPC principles apply there too. Our clinical team profiles are available on the clinical team page for anyone who wants to know who is doing the reviewing.